In Vivo Tumor Models

Charles River’s experience with oncology drug discovery spans all phases, from target identification to IND studies. Utilizing the most effective combination of tools available to identify promising compounds, we work with our partners to design studies by selecting from amongst a broad range of well-characterized tumor models.

In Vivo Cancer Models:

Combining these cancer models with appropriate translational tools like ELISpot, flow cytometry, imaging, gene expression analysis, and tumor microdialysis, you can develop the most efficient, relevant study design and screening method to identify promising compounds and optimize lead candidates.

Before entering traditional in vivo efficacy models, using pharmacodynamic models helps to ensure target engagement and immune modulation e.g., adoptive T cell transfer and Graft vs Host (GvHD) models. Cost-effective 2D and 3D assays allow you to screen compounds before entering in vivo tumor models.


Image of tumor for AACR 2021 signifying the oncology research done at Charles River

AACR Annual Meeting 2021

No matter the circumstances, cancer patients are waiting on new therapies. Browse this year's collection of scientific posters and resources so your oncology research can continue moving forward.

Keep Moving Forward


 

Accelerated In Vivo Screening of Early Compounds and Combination Therapies

New implantable microdevice (IMD) technology available through our partnership with Kibur Medical enhances your in vivo tumor studies the ability to efficiently and cost effectively administer and measure the effects of drugs injected directly into tumors. When used in animal models in the preclinical setting, this translational technology drives decisions with data that answers challenging questions about your drug’s performance – alone or in comparison/combination with other therapies – within the tumor microenvironment.

Implantable Microdevice Technology

CDX Models are tumor cell lines from commercial vendors or from patient-derived xenografts engrafted into immunodeficient mice.

In vivo implantable microdevice for oncology in vivo tumor models

Delivering microdoses of multiple drugs directly to diseased tissue, Kibur’s IMD allows us to measure the real-time effects of therapy on the surrounding tissue. Predict an optimal drug regimen, faster and at lower cost by simultaneously screening multiple combinations in a single animal.

Multiple micro-chambers in each device can be loaded with up to 18 different drugs per tumor (single agents or combination therapies). Designed to detect local drug effects in disease tissue in vivo, IMD technology offers numerous advantages:

  • Investigate more compounds per study
  • Minimize mouse requirements
  • Make decisions faster
  • Obtain and monitor precise spatial-specific data on local effects of therapy
  • Screen early-stage compounds for efficacy/PD in a variety of disease contexts/tissues/organs
  • Screen or study multiple drugs in addition to systemic treatment
  • Test drugs which can't be tested systemically because of PK or toxicology

Download our datasheet on Intratumor microdevices for highly multiplexed in situ drug response measurements.

Explore Your Options

Charles River is driving oncology drug discovery across a range of modalities including small molecules, immune therapies, biologics, cell therapies. At our BSL2 facilities we're even working on viral vectors and cancer vaccines.

Frequently Asked Questions (FAQs) about Cancer Models